Introduction {#sec1_1}
============

Worldwide, the prevalence of being overweight (i.e., a BMI of 25-29.9 kg/m^2^) or obese (BMI ≥ 30 kg/m^2^) is rapidly increasing across all age, gender, and racial groups \[[@B1]\]. Ample studies have shown that being overweight or obese is associated with many chronic diseases such as arthritis \[[@B2]\], certain cancers \[[@B3]\], and sleep apnoea \[[@B4]\]. Further, it has been shown that these adiposity categories are associated with cardiovascular diseases (CVD). High levels of BMI have consistently been found to be strong risk factors, amongst others, for hypertension \[[@B5]\] and stroke \[[@B6]\]. However, markers of low-grade inflammation might in part explain these relationships \[[@B7],[@B8]\]. Well-known examples of such markers include C-reactive protein (CRP) and fibrinogen.

CRP is a protein produced in the liver in response to inflammation or due to increased adipocyte activity \[[@B9],[@B10]\]. The protein has been extensively investigated, especially by cross-sectional studies, and CRP has been shown to be elevated in obese individuals from various study populations \[[@B9],[@B10],[@B11]\]. Moreover, CRP has also been found to be an independent marker of elevated CVD risk \[[@B9],[@B12]\]. Fibrinogen, which is also produced in the liver, is a marker of both inflammation and haemostasis and is known to predict future CVD as well \[[@B13]\]. Studies investigating fibrinogen and adiposity demonstrated elevated fibrinogen values in overweight and obese individuals \[[@B14]\].

Many longitudinal studies have shown that weight gain \[[@B15],[@B16]\] and greater weight variability over time \[[@B17],[@B18]\] are associated with an increase in levels of several low-grade inflammation markers, whereas others did not find any association at all \[[@B19]\]. These inconsistent findings are one of the reasons why weight variability research remains of high interest; in addition this is partly driven by the rapid progress that has been made in the statistical analysis of longitudinal data. Up to date techniques, i.e., latent class growth models (LCGM), make possible the analysis of distinct BMI trajectories and of subsequent associations with markers of low-grade inflammation. It has recently been shown \[[@B20],[@B21],[@B22]\] that the development of BMI is heterogeneous over time, where not only weight loss or weight gain in itself but also distinct trajectories of BMI may be of importance for the quantification of various health risks. For example, Mustillo et al. \[[@B23]\] identified four distinct obesity trajectories in a cohort of 9- to 16-year-old children, each with distinct consequences for psychopathology. Further, Kuchibhatla et al. \[[@B24]\] identified three distinct trajectories of BMI in a cohort of elderly participants, whereas Botoseneanu and Liang \[[@B25]\] identified five distinct trajectories in a cohort of subjects of similar age. In all studies, distinct trajectories of BMI coincided with differential health or disease consequences. Given the increasing obesity epidemic, investigating the subsequent health and disease consequences of distinct BMI trajectories in a range of cohorts is critical. Particularly the possibility to identify high-risk individuals who may need supplementary treatment or preventive measures in addition to the standard care or prevention is important. In this light, the evaluation of (health and disease consequences of) distinct trajectories might also allow for the identification of low-risk individuals who need less treatment. Using 'conventional' statistical approaches (e.g., calculating BMI change scores) would probably mask this heterogeneity in development.

The aim of the current study was twofold: First, we analysed the heterogeneity of BMI development over time, thereby determining the number and characteristics of distinct developmental patterns of BMI in an adult study population. Secondly, we related these distinct subgroups to late-life CRP- and fibrinogen levels, revealing subgroups specifically at risk for future CVD.

Material and Methods {#sec1_2}
====================

The Spokane Heart Study {#sec2_1}
-----------------------

The Spokane Heart Study is a longitudinal study of healthy local participants investigating the development of pre-clinical atherosclerosis in order to predict the risk for coronary artery disease from traditional and non-traditional factors \[[@B26],[@B27],[@B28],[@B29]\]. Beginning in 1994, participants were enrolled every 2 years until 2006, and data was collected at 2-year intervals. Visits therefore took place in different years for different participants, and not all participants were followed up an equal number of times. In total, 1,147 participants in the Spokane Heart Study were visited at least once.

The study was reviewed and approved by the institutional review board of the participating university and community hospitals, and written informed consent was given by all participants at all measurement occasions. For consistency in sample sizes over time and to avoid possible period effects, only visits 1-4 were analysed. Participants who had multiple (three or more) measurements \[[@B22]\] of body weight over time (n = 441) and from whom valid blood samples were available (n = 407) were included. The characteristics of this selection were compared to the 1,147 participants of the Spokane Heart Study and, at the first visit, showed no relevant differences on BMI, CRP or fibrinogen (BMI: 26.66 ± 4.42 kg/m^2^ vs. 27.24 ± 4.39 kg/m^2^; CRP: 2.5 ± 3.80 mg/dl vs. 2.87 ± 3.60 mg/dl; fibrinogen: 319.73 ± 207.29 mg/dl vs. 321.78 ± 124.24 mg/dl).

In total, 203 (49.9%) women and 204 men were included in the study. Participants in the Spokane Heart Study were predominately Caucasian (\>98%), and the obesity rates at visit 1 (16.2%) conducted around 1994 for this sample were comparable to the nationwide obesity rates (14.4%) \[[@B30]\].

Adiposity {#sec2_2}
---------

Adiposity was quantified by means of the BMI. The BMI was calculated by dividing body mass (kg) by height squared (meters). Body mass was measured using a calibrated scale, and height was measured using a wall-mounted stadiometer, generally available at community hospitals throughout the USA.

C-Reactive Protein and Fibrinogen {#sec2_3}
---------------------------------

Fasting blood samples were collected in the morning of visit 1 as well as visit 4 and separated into serum and plasma by centrifugation. High-sensitivity CRP in plasma was analysed using nephelometric assays at the Center for Disease Control and Prevention (CDC), Atlanta, GA, USA. As recommended by the CDC and the American Heart Association, levels \> 10 mg/dl were not included in the analyses because they may indicate active infection or trauma \[[@B31]\]. Fibrinogen was analysed by the Pathology Associates Medical Laboratory, a nationally certified laboratory in Spokane, WA, and also expressed in mg/dl.

Covariates {#sec2_4}
----------

Baseline lifestyle covariates were utilised. Smoking status was asked in a questionnaire, and it was stated whether the participant was a smoker or a non-smoker. Physical exercise levels were determined by a self-report questionnaire measuring the extent of engagement in several sports activities. The answers to all questions were combined to form a binary variable indicating whether or not a participant engaged regularly (approximately 5 h/week, including all levels of intensity according to the 2008 physical activity guidelines for adults developed by the CDC control) in sportive activities. Dietary information was determined by a self-report questionnaire asking whether the participant was on a restricted diet (i.e., low-fat and/or low-salt and/or low-cholesterol and/or vegetarian); accordingly, a binary variable (restricted diet yes/no) was included in the analyses. Information on current oral contraceptive usage (females only) was obtained by a self-report questionnaire and scored as a binary variable (users versus non-users). Information on usage of other relevant medication known to influence low-grade inflammation (i.e., blood pressure medication, cholesterol medication, and diabetes medication) was obtained from a self-report questionnaire. This variable was also binary coded and included in the analyses as such.

Possible effect modification by gender was assessed by creating interaction terms (class membership dummies × gender) and evaluating their p values.

Statistical Methods {#sec2_5}
-------------------

Analyses were conducted using the Mplus 7.0 \[[@B32],[@B33]\] and the PASW 20.0 software packages.

Analyses were conducted in two steps. All continuous outcome variables were checked for normality and log transformed if necessary, and all assumptions underlying the analyses were checked. Significance results were given as two-sided p values unless stated otherwise, where a p value \< 0.05 was regarded as statistically significant.

Step 1 -- Latent Class Growth Modelling {#sec2_6}
---------------------------------------

In step 1, distinct developmental patterns of BMI were identified by means of LCGM \[[@B34],[@B35],[@B36],[@B37]\]. LCGM is an up to date statistical technique in obesity research. The aim of the technique is to capture the heterogeneity of BMI development over time in k numbers of subgroups (or classes) with comparable BMI development. Each subgroup has its own growth parameters (intercept, slope) which are unobserved (or latent) continuous variables.

Class Identification {#sec2_7}
--------------------

To determine the optimal number of latent classes, a forward procedure \[[@B22],[@B37]\] was performed, starting with a 1-class solution (i.e., there were no subgroups in the study sample; all individuals followed the same trajectory over time), then adding more classes one at a time to investigate whether or not the model fit improved due to the additional class. We used several model fit indices and other criteria to compare the fit between subsequent models, as suggested in the literature \[[@B38]\]. First, we used two model fit indices: the Bayesian information criterion (BIC) and the bootstrap likelihood ratio test (BLRT). The BIC is commonly used within latent variable modelling analyses, considering both the likelihood of the model as well as the number of parameters in the model; a lower BIC value shows a better model fit (a decrease of at least 10 points is suggested as sufficient improvement) \[[@B39]\]. The BLRT \[[@B40]\] provides a p value, indicating that a model with one less class (k -- 1-class model) has to be rejected in favour of the k class model. Both fit indices have proven to be consistent indicators of the optimal number of classes \[[@B38]\]. To further determine the optimal number of classes, we secondly looked at the posterior probabilities of belonging to each of the k classes \[[@B38]\]. Based on these probabilities, study participants were assigned to their most likely class, and only solutions with posterior probabilities of 0.8-0.9 or higher were accepted \[[@B37],[@B38]\]. The probability for the class the individual was assigned to should be considerably higher than the other probability/probabilities. In this way, the classes clearly differed from each other. Additionally, we considered the usefulness of the separate classes in practice. This was done in two ways: by examining the shape of the trajectories and by the number of individuals in each class. Clinically uninterpretable solutions were rejected in favour of interpretable solutions \[[@B37]\].

Step 2 -- Linear Regression Analyses {#sec2_8}
------------------------------------

The first step of the analyses provided us with a classification of the study population into distinct subgroups, based on the development of BMI. The classification was coded as a categorical variable with k numbers of categories or classes. To study the possible association between the distinct subgroups and CRP as well as fibrinogen, several linear regression analyses were performed with the markers of low-grade inflammation as outcome variables. First, 'crude' analyses were conducted in which class membership was related to CRP or fibrinogen, correcting only for age, gender, relevant medication use and oral contraceptive usage. Secondly, adjusted analyses were carried out, adding the lifestyle covariates to the regression model.

Results are were reported as unstandardised regression coefficients, indicating the mean difference in the markers of low-grade inflammation between the distinct trajectories of BMI. Corresponding 95% confidence intervals and two-sided p values are presented alongside.

The p values of the interaction terms investigating effect modification by gender were all non-significant (p = 0.05, 0.429, 0.616, 0.649 and 0.670), and therefore no stratification by gender was made.

Advantages of this Approach {#sec2_9}
---------------------------

LCGMs allow for the empirical identification and subsequent analysis of otherwise invisible distinct subgroups of individuals with similar BMI trajectories over time (see above).

Additional Analyses {#sec2_10}
-------------------

In order to determine if 'conventional' statistical approaches provided any further information and/or stronger, or weaker prediction of CRP and fibrinogen by BMI, we calculated change scores of BMI (BMI at visit 4 minus BMI at visit 1) and related this continuous variable to CRP and fibrinogen, using the regression analysis steps described above in step 2.

Results {#sec1_3}
=======

The 'best' model of the LCGM is visualised in figure [1](#F1){ref-type="fig"}. Based on the model fit indices and additional information available (see table [1](#T1){ref-type="table"}), selecting the 'best' model was relatively difficult because of some inconsistency in model fit indices. Based on the BIC, a 5-class solution could be considered as being the 'best' model, but the BLRT pointed towards a 6-class model. After taking into account the clinical interpretation of the 4-, 5- and 6-class models in particular, a final decision for the 6-class model was made, also because the BLRT had proven to be a very consistent model fit index \[[@B38]\]. Therefore, the best LCGM solution was a 6-class model, where most participants could be classified in a 'normative' class which is characterised by stable BMI values around 25 kg/m^2^. Subsequently, two more stable subgroups emerged: a stable obese (n = 96) and a stable severely obese (n = 15) subgroup. The stable obese subgroup was characterised by stable BMI values around 30 kg/m^2^, although slight increases were apparent after visit 2. The stable severely obese subgroup was characterised by stable BMI values of just under 40 kg/m^2^. Further, two groups commenced with a BMI increase which was then levelled off, starting at different baseline values (normal weight (n = 18) and obese (n = 8)). The first subgroup showed a steep increase between visit 1 and 3 (approximately 7 BMI points); an increase of similar extent was visible for the latter.

Finally, a small group (n = 2) showed a decrease from an obese baseline state (BMI values between 30 and 35 kg/m^2^) towards a 'normative' state (BMI values similar to the normative subgroup). Because of the small sample size, this class was not analysed further. The fit information of the BIC, BLRT, posterior probabilities and number of subjects per class are visualised in table [1](#T1){ref-type="table"}.

Characteristics of the five classes are shown in table [2](#T2){ref-type="table"}, including the 95% confidence intervals around the estimated BMI values of each class at each visit as demonstrated in figure [1](#F1){ref-type="fig"}. It can be seen that the different trajectories do not differ a great deal on lifestyle variables, although the increasing to severely obese trajectory represents the only class with no smokers. Furthermore, this class had the highest number of subjects on a restricted diet (i.e., low-salt, low-fat, low-cholesterol or vegetarian), and the number of subjects engaging in sports activities was comparable to that of subjects classified into the normative trajectory.

The results of the associations between the BMI trajectories and CRP/fibrinogen at visit 4 are shown in tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. In all models, the normative subgroup was used as the reference category. For CRP, all subgroups showed significantly higher values in model 1 (1.84-3.04 times higher) when compared to the normative subgroup. Correcting for relevant lifestyle variables did not affect these associations considerably. For fibrinogen, the results showed a slightly different picture. Although all subgroups displayed higher levels of fibrinogen compared to the normative subgroup (between 19.83 and 155.25 mg/dl higher in model 1), only the difference between the increasing to severely obese and the normative subgroup was statistically significant, and the difference between the normative and the stable severely obese subgroup was borderline significant (p = 0.069).

To evaluate the importance of the BMI trajectories relative to each other, the above analyses were also run with different reference categories. Interestingly, the 'unfavourable' trajectories only differed slightly from each other on both CRP and fibrinogen levels, although differences in fibrinogen levels were more profound. When comparing the stable obese and the increasing towards obesity trajectory (both showing similar BMI values at the last visit (table [2](#T2){ref-type="table"}), large differences in both CRP and fibrinogen were apparent, although these differences were only borderline significant. Further comparisons are not presented here, but can be partly drawn from the results presented in tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

In table [5](#T5){ref-type="table"}, the same analyses are presented as in table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, but with the calculated change scores of CRP and fibrinogen (visit 4 minus visit 1) as the outcome variables. Again, the normative trajectory was set as the reference category. For CRP, much smaller regression coefficients appeared, and only the difference in change scores between the increasing to obese and the normative trajectory was statistically significant. This regression coefficient was, however, difficult to interpret; 1.41 can be interpreted as the difference in CRP change score between the increasing to obese trajectory and the normative trajectory, indicating that the former subgroup increased more in CRP over time (table [2](#T2){ref-type="table"}). For fibrinogen, smaller regression coefficients were observed, in particular the regression coefficient comparing the change scores of the stable severely obese and the normative subgroups (table [2](#T2){ref-type="table"}).

The additional analyses or the results of 'conventional' analyses are presented in tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}. Change scores of BMI were calculated and related to CRP and fibrinogen levels at visit 4 in table [6](#T6){ref-type="table"}. This table shows that BMI change scores were positively associated with CRP and fibrinogen levels at visit 4, although regression coefficients were only statistically significant for analyses with CRP. This regression coefficient (adjusted; model 2) can be interpreted as follows: an increase in BMI change score of 1 point between visits 1 and 4 resulted in 1.11 times higher CRP levels at visit 4, whereas for fibrinogen this resulted in a by 3.65 mg/dl higher level.

Small effects are also shown in table [7](#T7){ref-type="table"}, where the outcome variable is the change score of CRP/fibrinogen. An increase in the BMI change score of 1 point was associated with an increase of 0.19 mg/dl in CRP change score and 5.48 mg/dl in fibrinogen change score (again, the analyses with CRP were statistically significant and those with fibrinogen were not).

Discussion {#sec1_4}
==========

The current study investigated the heterogeneity of BMI development over 6 years. We identified six distinct developmental trajectories of BMI. Subsequently, we assessed the associations between these trajectories and CRP and fibrinogen levels determined at visit 4 as well as change scores of these levels. 'Unfavourable' BMI trajectories differed to a great extent from the normative trajectory with regard to CRP and fibrinogen levels at visit 4, but to a much lesser extent with regard to their CRP and fibrinogen change scores. When 'conventional' analyses were conducted (i.e., replacing the BMI trajectories by BMI change scores), much smaller regression coefficients were observed.

Heterogeneity in BMI Development and Low-Grade Inflammation {#sec2_11}
-----------------------------------------------------------

To our knowledge, this is the first population-based study that investigated the effects of distinct trajectory shapes of adiposity on markers of low-grade inflammation. There are some studies exploring the relationship between the development of adiposity and markers of low-grade inflammation, such as CRP and fibrinogen, over time. However, although a number of studies is available, comparison with these studies is difficult for two important reasons. First, definitions of adiposity development are inconsistent across studies. For example, some researchers categorised study participants in arbitrary subgroups and pulled participants who lost weight throughout the follow-up period together with stable-weight participants \[[@B41]\], whereas others categorised according to established criteria \[[@B16]\]. In some studies, only change scores were calculated \[[@B42]\] when examining the development of body weight over time. Second, many terms for weight instability, such as weight variability, weight fluctuation or weight cycling, are used, but it is unclear if and how these definitions vary. Although the statistical methodology and/or definition differs between these studies, they mostly point consistently to negative health consequences, including death, when increased weight variability, weight cycling, weight fluctuation or weight increase is apparent \[[@B42],[@B43]\]. While these studies allow for interesting and valuable results, they do not give insight in the trajectory of adiposity from the beginning to the end of follow-up and its effects on CRP or fibrinogen levels. Importance of these trajectories for traditional CVD markers \[[@B44],[@B45]\] and psychological health \[[@B21],[@B23],[@B46]\] has been highlighted previously and should not remain unnoticed in this setting either. In our study, we found six classes of BMI development, each with a distinct trajectory. Comparable trajectories were found in previous cohorts consisting of children and older adults in particular. For example, Kuchibhatla et al. \[[@B24]\] analysed a community-based sample aged 65-105 years and identified a normal-weight, an overweight and an obese trajectory, but failed to detect increasing trajectories. Stable trajectories comparable to our trajectories were identified by Botoseneanu and Liang \[[@B25]\], Rosenberger et al. \[[@B47]\] and Mustillo et al. \[[@B23],[@B46]\], whereas trajectories showing more variation over time were revealed in other studies \[[@B20],[@B23],[@B46],[@B48]\]. Generally, trajectories of similar shape are found across different cohorts, and decreasing trajectories are scarcely detected in observational studies. As found also in other studies \[[@B11],[@B16],[@B49]\], the 'unfavourable' classes (i.e., increasing trajectories or stable overweight/obese trajectories) in our study showed higher levels of low-grade inflammation markers compared to the normative class. Interestingly, however, the 'unfavourable' trajectories did not differ significantly from each other. Moreover, although the BMI trajectories clearly differed with respect to their visit-1- and visit-4 values of CRP and fibrinogen, the increase in these markers differed only slightly over time; it appeared that only the two increasing trajectories (although not to the same extent) differed from the normative trajectory with regard to their CRP and fibrinogen change scores. As BMI and CRP in particular were hypothesised to be associated longitudinally, it can be concluded that stable trajectories would not necessarily have increased change scores. This can also be seen in table [2](#T2){ref-type="table"} where descriptive information by BMI trajectory is represented. These findings highlight the fact that the sole analysis of change scores can be misleading if no actual change over time is apparent in the sample, even though baseline differences are clear.

Even though we identified six distinct trajectories of body weight development, where some showed degrees of variation in trajectory, these trajectories were all still relatively stable regarding their development of BMI. Therefore, we should be aware of the fact that the lack of variation in longitudinal development in this sample may mask even larger differences in CRP or fibrinogen levels, although trajectories with greater variation are generally found in younger cohorts \[[@B23],[@B46],[@B50]\] and cohorts with a very long follow-up period \[[@B51]\].

By the classification of the participants in six distinct trajectory classes, information on the course of BMI during visits 1, 2, 3 and 4 were taken into account, which is ignored when analysing BMI development using change scores. Therefore, the elevated CRP values in the stable trajectories (i.e., including subjects that do not change over time) will only have been detected by this approach and would have partly been obscured, if we had performed an analysis solely with BMI change scores. However, categorisation of subjects in six distinct subgroups did cause some information loss, highlighting the importance of both approaches.

Methodological Issues: Strengths and Limitations {#sec2_12}
------------------------------------------------

We used observational data collected at multiple times to investigate our research questions as thoroughly as possible. We had information on important confounders (e.g., oral contraceptive use, medication use, lifestyle factors) and were able to correct for those in our models, although we obtained information on these factors (that are known to influence low-grade inflammation) at baseline only, but not continuously throughout the follow-up period. Further, we used up to date statistical techniques to unravel heterogeneity in adiposity development. LCGM categorise participants on the basis of their developmental pattern instead of being based on predefined subgroups \[[@B37],[@B52]\]. These techniques have shown to be very promising for applications within obesity research \[[@B21],[@B22],[@B23],[@B46],[@B53],[@B54]\] and do provide researchers as well as clinicians with new insights for further research, in particular due to their data-driven nature. The 'unfavourable' trajectories that were identified with LCGM in our study are mostly based on relatively few participants (n = 8, 15 and 18). Although these are positive findings in terms of public health, small sample sizes do challenge elaborate statistical analyses. These small sizes might further complicate the generalizability of the BMI trajectories. Surprisingly, subjects classified into the increasing to severely obese trajectory (n = 8) reported a relatively healthy lifestyle (non-smoking, high sports participation, often restricting their diets), but still increased approximately 8 BMI points over 8 years. These findings could either suggest socially desirable answering \[[@B55]\] or might point towards a non-representative subgroup.

The importance of body fat distribution, as opposed to BMI, for the quantification of CVD risk has been highlighted in many studies \[[@B56],[@B57]\]. Unfortunately, the Spokane Heart Study did not provide any information on body fat distribution available for the visits we used in the current study. Although some studies reported that associations between measures of fat distribution, such as waist circumference, and measures of CVD were stronger compared to associations between BMI and measures of CVD \[[@B58]\], others found associations of similar strength, especially for Caucasian persons \[[@B59]\]. Nevertheless, the utilisation of BMI as a measure of adiposity is very common in scientific research as well as within the World Health Organization (WHO), allowing for a broad comparison of the results. This is especially relevant for body weight/adiposity trajectory research, where BMI is the most common adiposity measure. It should be noted, however, that BMI does not appropriately quantify the ratio between fat mass and fat-free mass, which additionally considers other factors such as nutritional status and cardio-respiratory fitness that are known to affect cardiovascular morbidity and mortality.

Conclusions and Implications {#sec2_13}
----------------------------

In conclusion, the results of this study show that in a community-based sample of males and females the development of BMI is heterogeneous; six distinct trajectory shapes could be identified. Statistically significant differences in CRP and fibrinogen levels were apparent between the trajectories, where the 'unfavourable' trajectories differed from the normative trajectory and differences were more profound for CRP than for fibrinogen. Our identified BMI trajectories partly confirm previous findings from studies with varying subject characteristics, and many studies demonstrated negative health consequences in relation to 'unfavourable' trajectories \[[@B20],[@B23],[@B46]\]. Clinical research could, therefore, explore the clinical utility of these distinct trajectories, relative to each other, in disease tracking and management systems. Overall, more longitudinal research is needed to understand the short- and long-term benefits and risks associated with sustained weight loss, weight gain and weight fluctuation.
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###### 

Model fit indices

  Number of classes   Bayesian information criterion   Bootstrapped likelihood ratio test   Average posterior probability (min-max)   Number of subjects per class
  ------------------- -------------------------------- ------------------------------------ ----------------------------------------- ------------------------------
  1                   7,604.838                        not available                        1.00                                      407
  2                   7,561.913                        \<0.001                              0.916 (0.843--0.988)                      385/22
  3                   7,532.887                        \<0.001                              0.933 (0.873--0.986)                      8/377/22
  4                   7,524.385                        \<0.001                              0.922 (0.824--1.00)                       15/2/27/363
  5                   7,521.011                        \<0.001                              0.897 (0.821--1.00)                       2/13/16/364/12
  6                   7,527.809                        0.08                                 0.869 (0.790--1.00)                       2/15/268/8/18/96

###### 

Characteristics of the distinct developmental patterns of BMI identified in the Spokane Heart Study

                                                                                                                  Normative              Increasing to obese    Stable obese           Increasing to severely obese   Stable severely obese
  --------------------------------------------------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ------------------------------ -----------------------
  Sample size                                                                                                     268                    18                     96                     8                              15
  Age at baseline                                                                                                 48.63 (9.82)           44.11 (8.55)           48.30 (8.00)           51.38 (3.85)                   49.67 (5.43)
  BMI, kg/m^2^                                                                                                                                                                                                        
   At visit 1[^6^](#T2F6){ref-type="table-fn"}                                                                    24.55 (24.23--24.84)   23.94 (22.71--25.18)   30.29 (29.91--30.67)   35.00 (32.77--37.23)           39.00 (36.89--41.11)
   At visit 2[^6^](#T2F6){ref-type="table-fn"}                                                                    24.90 (24.56--25.25)   27.56 (26.12--29.00)   31.00 (30.45--31.55)   38.00 (35.39--40.61)           39.07 (37.11--41.46)
   At visit 3[^6^](#T2F6){ref-type="table-fn"}                                                                    25.24 (24.93--25.54)   30.50 (29.14--31.86)   32.04 (31.63--32.45)   40.62 (37.95--43.30)           39.36 (37.47--41.25)
   At visit 4[^6^](#T2F6){ref-type="table-fn"}                                                                    25.54 (25.22--25.84)   31.00 (29.19--32.81)   31.87 (31.47--32.28)   41.88 (39.03--44.72)           37.87 (34.33--41.39)
  CRP, mg/dl                                                                                                                                                                                                          
   At visit 1[^1^](#T2F1){ref-type="table-fn"}                                                                    1.65 (1.71)            1.85 (2.05)            2.46 (1.95)            4.43 (2.30)                    4.30 (2.53)
   At visit 4[^1^](#T2F1){ref-type="table-fn"}                                                                    1.92 (2.07)            3.75 (2.45)            3.10 (2.33)            4.41 (3.17)                    3.95 (2.74)
  Difference in CRP (visit 4-visit 1)[^1^](#T2F1){ref-type="table-fn"}                                            0.26 (2.09)            1.90 (2.14)            0.57 (2.34)            −0.029 (4.15)                  −0.41 (2.38)
  Fibrinogen, mg/dl                                                                                                                                                                                                   
   At visit 1[^1^](#T2F1){ref-type="table-fn"}                                                                    316.10 (239.33)        317.81 (100.73)        310.52 (120.11)        420.34 (151.01)                397.68 (91.27)
   At visit 4[^1^](#T2F1){ref-type="table-fn"}                                                                    346.10 (124.10)        390.56 (94.09)         360.39 (157.39)        490.10 (201.60)                433.99 (105.61)
  Difference in fibrinogen (visit 4-visit 1)[^1^](#T2F1){ref-type="table-fn"}                                     30.27 (249.73)         72.75 (116.62)         47.65 (127.85)         69.76 (161.75)                 36.31 (98.43)
  \% Female[^2^](#T2F2){ref-type="table-fn"}                                                                      50.7                   61.1                   40.6                   37.5                           86.7
  \% Current smokers at visit 1[^2^](#T2F2){ref-type="table-fn"}                                                  8.6                    11.1                   9.4                    0.0                            6.7
  \% Regular engagement in sports at visit 1[^2^](#T2F2){ref-type="table-fn"},[^3^](#T2F3){ref-type="table-fn"}   38.60                  27.80                  22.80                  37.5                           13.30
  \% Restricted diet at visit 1[^2^](#T2F2){ref-type="table-fn"},[^4^](#T2F4){ref-type="table-fn"}                51.5                   55.6                   40.6                   75.0                           53.3
  \% Medication use at visit 1[^2^](#T2F2){ref-type="table-fn"},[^5^](#T2F5){ref-type="table-fn"}                 12.3                   0.00                   13.5                   62.5                           33.3

Continuous variables are presented as means (SD).

Categorical variables are presented as %.

Regular engagement implies approximately 5 h/week.

Restricted diets included low fat, low salt, low cholesterol or vegetarian.

Relevant medication include medication for cholesterol, blood pressure and/or diabetes.

95% confidence intervals are presented for the BMI values at visit 1--4.

###### 

Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory membership and CRP

                                                                  Model 1[^a^](#T3F1){ref-type="table-fn"}   Model 2[^b^](#T3F2){ref-type="table-fn"}                                 
  --------------------------------------------------------------- ------------------------------------------ ------------------------------------------ --------- ------ ------------ ---------
  Increasing to obese[^c^](#T3F3){ref-type="table-fn"}            2.22                                       1.38, 3.58                                 0.001     2.10   1.32, 3.36   0.002
  Stable obese[^c^](#T3F3){ref-type="table-fn"}                   1.84                                       1.45, 2.33                                 \<0.001   1.72   1.36, 2.17   \<0.001
  Increasing to severely obese[^c^](#T3F3){ref-type="table-fn"}   3.04                                       1.49, 6.20                                 0.002     3.24   1.61, 6.54   0.001
  Stable severely obese[^c^](#T3F3){ref-type="table-fn"}          2.35                                       1.39, 3.97                                 0.002     2.20   1.32, 3.36   0.003

Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.

Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).

'Normative' trajectory is set as the reference category.

Regression coefficients represented as ratios because of log-transformed CRP.

###### 

Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory membership and fibrinogen

                                                                  Model 1[^a^](#T4F1){ref-type="table-fn"}   Model 2[^b^](#T4F2){ref-type="table-fn"}                                     
  --------------------------------------------------------------- ------------------------------------------ ------------------------------------------ ------- -------- ---------------- -------
  Increasing to obese[^c^](#T4F3){ref-type="table-fn"}            48.19                                      −19.91, 116.29                             0.165   43.14    −25.86, 112.13   0.220
  Stable obese[^c^](#T4F3){ref-type="table-fn"}                   19.83                                      −12.91, 52.57                              0.234   19.85    −13.49, 53.19    0.242
  Increasing to severely obese[^c^](#T4F3){ref-type="table-fn"}   155.25                                     55.86, 254.63                              0.002   153.42   53.48, 253.37    0.003
  Stable severely obese[^c^](#T4F3){ref-type="table-fn"}          68.40                                      −5.30, 142.10                              0.069   69.35    −5.11, 143.81    0.068

Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.

Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).

'Normative' trajectory is set as the reference category.

###### 

Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory and change scores of CRP and fibrinogen

                                                                  CRP     Fibrinogen                                      
  --------------------------------------------------------------- ------- ------------- ------- ------- ----------------- -------
  *Model 1*                                                                                                               
  Increasing to obese[^c^](#T5F1){ref-type="table-fn"}            1.41    0.37, 2.46    0.008   44.64   −69.40, 158.69    0.442
  Stable obese[^c^](#T5F1){ref-type="table-fn"}                   0.26    −0.27, 0.80   0.336   16.83   −38.70, 71.70     0.547
  Increasing to severely obese[^c^](#T5F1){ref-type="table-fn"}   0.24    −1.32, 1.80   0.760   79.28   −87.08, 245.64    0.349
  Stable severely obese[^c^](#T5F1){ref-type="table-fn"}          −0.22   −1.45, 1.01   0.727   9.98    −113.38, 133.34   0.874
                                                                                                                          
  *Model 2*                                                                                                               
  Increasing to obese[^c^](#T5F1){ref-type="table-fn"}            1.36    0.32, 2.41    0.011   49.02   −66.57, 164.60    0.405
  Stable obese[^c^](#T5F1){ref-type="table-fn"}                   0.17    −0.37, 0.72   0.532   17.04   −38.84, 72.92     0.549
  Increasing to severely obese[^c^](#T5F1){ref-type="table-fn"}   0.34    −1.23, 0.90   0.673   84.89   −82.43, 252.22    0.319
  Stable severely obese[^c^](#T5F1){ref-type="table-fn"}          −0.29   −1.52, 0.95   0.650   10.78   −113.87, 135.43   0.865

^a^Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.

^b^Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).

'Normative' trajectory is set as the reference category.

###### 

Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between change scores of BMI and CRP and fibrinogen levels at visit 4

  -----------------------------------------------------------------------------
                     CRP    Fibrinogen                                  
  ------------------ ------ ------------ --------- ------ ------------- -------
  *Model 1a*\        1.10   1.06, 1.15   \<0.001   3.73   −1.69, 9.15   0.177
  BMI change score                                                      

                                                                        

  *Model 2b*\        1.10   1.06, 1.15   \<0.001   3.65   −1.81, 9.12   0.189
  BMI change score                                                      
  -----------------------------------------------------------------------------

^a^Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use

^b^Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour)

###### 

Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between change scores of BMI and change scores of CRP and fibrinogen levels

  ------------------------------------------------------------------------------
                     CRP    Fibrinogen                                   
  ------------------ ------ ------------ --------- ------ -------------- -------
  *Model 1a*\        0.18   0.09, 0.27   \<0.001   5.01   −3.92, 13.94   0.271
  BMI change score                                                       

                                                                         

  *Model 2b*\        0.19   0.10, 0.27   \<0.001   5.48   −3.51, 14.47   0.232
  BMI change score                                                       
  ------------------------------------------------------------------------------

^a^Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.

^b^Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).
